Filing Flows › Exagen (XGN) › Q2 2026 › vs Q1 2026
Exagen (XGN) Q2 2026 vs Q1 2026 (quarter over quarter)
Exagen's revenue rose $2.6M (+15%) from $17.3M in Q1 2026 to $19.9M in Q2 2026.
Exagen, Q2 2026: revenue $19.9M (+16% year over year), operating margin -8.6%, net loss $3.2M, operating cash flow $4.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.3% | -61.5% | +78.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $19.9M | $17.3M | $2.6M | +15% |
| Net loss | $3.2M | $4.0M | −$771K | -19% |
| Costs & expenses | $23.1M | $21.3M | $1.9M | +9% |
| Operating costs | $21.7M | $20.7M | $943K | +5% |
| Interest & other, net | $1.5M | $517K | $957K | +185% |
| Cost of revenue | $7.7M | $7.1M | $623K | +9% |
| Research & development | $1.4M | $1.6M | −$127K | -8% |
| SG&A | $12.5M | $12.1M | $447K | +4% |
| Operating cash sources | $7.2M | −$6.5M | $13.6M | — |
| Depreciation & amortization | $600K | $600K | $0 | 0% |
| Share-based compensation | $980K | $655K | $325K | +50% |
| Working capital & other | $5.6M | −$7.7M | $13.3M | — |
| Net loss absorbed | $3.2M | $4.0M | −$771K | -19% |
| Operating cash flow | $4.0M | −$10.4M | $14.4M | — |
| Free cash flow (OCF − capex) | $3.4M | −$10.6M | $14.1M | — |
| Capital expenditures | $543K | $228K | $315K | +138% |
Questions
How much did Exagen's revenue grow quarter over quarter in Q2 2026?
Exagen's revenue rose $2.6M (+15%) from $17.3M in Q1 2026 to $19.9M in Q2 2026.